1. Baraldi F, Contoli M, Papi A. The Convoluted Journey to Unveil the Respiratory Syncytial Virus in Chronic Obstructive Pulmonary Disease Exacerbations: Old Paths and New Traces. Am J Respir Crit Care Med. 2024;210(8):967-9.
2. Kurai D, Saraya T, et al. Virus-induced exacerbations in asthma and COPD. Front Microbiol. 2013 Oct 1;4:293. doi: 10.3389/fmicb.2013.00293. PMID: 24098299; PMCID: PMC3787546.
3. Jain H, Schweitzer JW, et al. Respiratory Syncytial Virus Infection in Children. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK459215/
4. Surie D, Yuengling KA, et al. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Netw Open. 2024 Apr 1;7(4):e244954.
5. Wilson E, Goswami J, et al. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023 Dec 14;389(24):2233-2244. doi: 10.1056/NEJMoa2307079. PMID: 38091530.
6. Topalidou X, Kalergis AM, et al. Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines. Pathogens. 2023 Oct 19;12(10):1259.
7. Hewitt R, Farne H, et al. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10(2):158-74.
8. Wiseman DJ, Thwaites RS, et al. Respiratory Syncytial Virus-related Community Chronic Obstructive Pulmonary Disease Exacerbations and Novel Diagnostics: A Binational Prospective Cohort Study. Am J Respir Crit Care Med. 2024;210(8):994-1001.
9. Reis J, Shaman J. Retrospective Parameter Estimation and Forecast of Respiratory Syncytial Virus in the United States. PLoS Comput Biol. 2016;12(10):e1005133.
10. Novak N, Cabanillas B. Viruses and asthma: The role of common respiratory viruses in asthma and its potential meaning for SARS-CoV-2. Immunology. 2020;161:83–93.
11. Tseng HF et al. 2020. J Infect Dis, 222, 1298-1310.
12. Nguyen-Van-Tam JS, O'Leary M, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev. 2022 Nov 15;31(166):220105.
13. Premalatha P, Shadia HA, et al. The wake of the triple epidemic (Tripledemic): does it emphasizes the COVID-19 vaccine as a routine immunization for children? - A cross-sectional study. Eur Rev Med Pharmacol Sci. 2023;27(16):7840-7850.
14. Ison MG, Papi A, et al; AReSVi-006 Study Group. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744.
15. Leroux I, et al. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial. J Inf Disease 2023:227.
16. Feldman R, Antonelli R, Steenackers K, Lee D, et al. Raffaele Antonelli-Incalzi, Respiratory Syncytial Virus Prefusion F Protein Vaccine is Efficacious in Older Adults With Underlying Medical Conditions. CID 2024:78.
17. Ison M, Papi A, et al. on behalf of the AReSVi-006 study group. The Efficacy of a Single Dose of the Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults ≥60 Years of Age Over 3 RSV Seasons. Poster 3391 presented at CHEST 2024 – (2024 October 6-9), Boston, United States.
18. Savic M. Et al. Influenza Other Rspir Viruses 2023:17:e13031.